Search results
Adding Isatuximab to Standard Backbone Improves Outcomes in Multiple Myeloma
MedPage Today· 2 days agoTwo trials show positive outcomes
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days agoNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of
A malaria drug may combat tick-borne babesiosis
Medical Xpress· 9 hours agoThe drug tafenoquine helped cure four New England patients whose babesiosis infections weren't knocked out by the usual standard of care ...
Ozempic and Wegovy could double as kidney disease treatment, study suggests
Fox News· 6 days agoThe study, funded by Novo Nordisk and published in The New England Journal of Medicine, included ...
Novel Drug Reduces Steroid Need in Congenital Adrenal Hyperplasia
MedPage Today· 4 days agoBoth trials were presented at ENDO 2024, the annual meeting of The Endocrine Society, and...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 12 hours agoIn a recent study led by Suresh Ramalingam, MD, executive director of Winship Cancer Institute of Emory University, a new drug has shown ...
From immunotherapy to mRNA vaccines—the latest science on melanoma treatment explained
Medical Xpress· 10 hours agoOver the past decade, these treatments have seen a significant climb in the number of advanced...
Existing drug shows promise as treatment for rare genetic disorder
Medical Xpress· 6 days agoIn a three-stage study, conducted in mice and people, the researchers examined how APS-1 causes...
You Can Toss Out Everything You’ve Ever Learned About How Your Tongue Works — Here’s What to Know
Food & Wine via Yahoo News· 3 days agoGetty The way to someone’s heart may be through their stomach. But it also may be through their...
Hereditary Angioedema Attacks Reduced With Donidalorsen Prophylaxis
MedPage Today· 6 days agoThe median reduction in the attack rate from baseline was 90% in the 4-week group, 83% in the 8-week...